Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1574

1.

Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.

Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD Jr, Shore RE; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group, Bernstein JL.

J Natl Cancer Inst. 2008 Jan 2;100(1):32-40. Epub 2007 Dec 25.

PMID:
18159070
[PubMed - indexed for MEDLINE]
Free Article
2.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG).

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
[PubMed - indexed for MEDLINE]
3.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG).

J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. Erratum in: J Natl Cancer Inst 2002 Sep 4;94(17):1339.

PMID:
12122096
[PubMed - indexed for MEDLINE]
Free Article
4.

Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N.

J Natl Cancer Inst. 2004 Apr 7;96(7):516-23.

PMID:
15069113
[PubMed - indexed for MEDLINE]
Free Article
5.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
[PubMed - indexed for MEDLINE]
Free Article
6.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A.

J Clin Oncol. 2000 Apr;18(7):1412-22.

PMID:
10735888
[PubMed - indexed for MEDLINE]
7.

Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.

Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L; South Swedish and South-East Swedish Breast Cancer Groups.

Eur J Cancer. 2009 Sep;45(14):2496-502. doi: 10.1016/j.ejca.2009.05.022. Epub 2009 Jun 15.

PMID:
19535242
[PubMed - indexed for MEDLINE]
8.

Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.

Johansen J, Overgaard J, Overgaard M.

Acta Oncol. 2007;46(4):525-33.

PMID:
17497320
[PubMed - indexed for MEDLINE]
9.

Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease.

van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS.

J Natl Cancer Inst. 2003 Jul 2;95(13):971-80.

PMID:
12837833
[PubMed - indexed for MEDLINE]
Free Article
10.

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, Cronin W, Wickerham DL.

J Natl Cancer Inst. 2004 Dec 1;96(23):1762-9. Erratum in: J Natl Cancer Inst. 2005 Jan 5;97(1):71.

PMID:
15572758
[PubMed - indexed for MEDLINE]
Free Article
11.

Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers.

Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR.

J Natl Cancer Inst. 1995 Sep 20;87(18):1359-64.

PMID:
7658496
[PubMed - indexed for MEDLINE]
12.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.

J Natl Cancer Inst. 2006 Jan 18;98(2):110-5.

PMID:
16418513
[PubMed - indexed for MEDLINE]
Free Article
13.

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group.

Lancet. 2000 Dec 2;356(9245):1876-81.

PMID:
11130383
[PubMed - indexed for MEDLINE]
14.

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Group.

J Clin Oncol. 2005 Nov 1;23(31):7842-8.

PMID:
16258087
[PubMed - indexed for MEDLINE]
15.

Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients: an update based on 10 years' follow-up. German Breast Cancer Study Group.

Sauerbrei W, Bastert G, Bojar H, Beyerle C, Neumann RL, Schmoor C, Schumacher M.

J Clin Oncol. 2000 Jan;18(1):94-101.

PMID:
10623698
[PubMed - indexed for MEDLINE]
16.

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.

J Natl Cancer Inst. 2007 Feb 21;99(4):283-90.

PMID:
17312305
[PubMed - indexed for MEDLINE]
Free Article
17.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
[PubMed - indexed for MEDLINE]
Free Article
18.

Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.

Adjuvant Breast Cancer Trials Collaborative Group.

J Natl Cancer Inst. 2007 Apr 4;99(7):506-15.

PMID:
17405995
[PubMed - indexed for MEDLINE]
Free Article
19.

Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.

Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP.

J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76.

PMID:
14519753
[PubMed - indexed for MEDLINE]
Free Article
20.

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, Knowling MA, Coppin CM, Weir L, Gelmon K, Le N, Durand R, Coldman AJ, Manji M.

J Natl Cancer Inst. 2005 Jan 19;97(2):116-26.

PMID:
15657341
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk